Path ID: DB05812_MESH_D011471_3
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000069501 | abiraterone acetate | Drug |
| UniProt:P15538 | Cytochrome P450 11B1, mitochondrial | Protein |
| UniProt:P08686 | Steroid 21-hydroxylase | Protein |
| UniProt:P05177 | Cytochrome P450 1A2 | Protein |
| UniProt:P11712 | Cytochrome P450 2C9 | Protein |
| UniProt:P08684 | Cytochrome P450 3A4 | Protein |
| GO:0006704 | glucocorticoid biosynthetic process | BiologicalProcess |
| GO:0061370 | testosterone biosynthetic process | BiologicalProcess |
| HP:0030088 | Increased serum testosterone level | PhenotypicFeature |
| MESH:D011471 | Malignant tumor of prostate | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Abiraterone Acetate | DECREASES ACTIVITY OF | Cytochrome P450 11B1, Mitochondrial |
| Abiraterone Acetate | DECREASES ACTIVITY OF | Steroid 21-Hydroxylase |
| Abiraterone Acetate | DECREASES ACTIVITY OF | Cytochrome P450 1A2 |
| Abiraterone Acetate | DECREASES ACTIVITY OF | Cytochrome P450 2C9 |
| Abiraterone Acetate | DECREASES ACTIVITY OF | Cytochrome P450 3A4 |
| Cytochrome P450 11B1, Mitochondrial | POSITIVELY REGULATES | Glucocorticoid Biosynthetic Process |
| Steroid 21-Hydroxylase | POSITIVELY REGULATES | Glucocorticoid Biosynthetic Process |
| Cytochrome P450 1A2 | POSITIVELY REGULATES | Glucocorticoid Biosynthetic Process |
| Cytochrome P450 2C9 | POSITIVELY REGULATES | Glucocorticoid Biosynthetic Process |
| Cytochrome P450 3A4 | POSITIVELY REGULATES | Glucocorticoid Biosynthetic Process |
| Glucocorticoid Biosynthetic Process | POSITIVELY CORRELATED WITH | Testosterone Biosynthetic Process |
| Testosterone Biosynthetic Process | POSITIVELY CORRELATED WITH | Increased Serum Testosterone Level |
| Increased Serum Testosterone Level | POSITIVELY CORRELATED WITH | Malignant Tumor Of Prostate |
Comment: In addition to inhibiting UniProt:P05093 (the main target according to https://go.drugbank.com/drugs/DB05812#mechanism-of-action),,) abiraterone also inhibits all these cytochrome P450s and can be useful in treating castration-resistant prostate cancers.
Reference: